Legend Biotech Corporation
LEGN
$32.80
-$0.66-1.97%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 134.56% | 66.60% | 151.27% | 149.90% | 189.43% |
| Total Other Revenue | 446.34% | 1,378.95% | 3,746.03% | 5,844.64% | -78.65% |
| Total Revenue | 134.73% | 66.86% | 154.36% | 158.67% | 187.57% |
| Cost of Revenue | 29.12% | 8.37% | 26.94% | 29.21% | 33.18% |
| Gross Profit | 113.92% | 121.27% | 142.53% | 26.68% | 22.89% |
| SG&A Expenses | 33.25% | 61.72% | 33.01% | 39.82% | 18.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.40% | 22.29% | 28.62% | 31.86% | 28.35% |
| Operating Income | 38.08% | 23.96% | 59.77% | 5.20% | 5.86% |
| Income Before Tax | 127.59% | -93.43% | 90.96% | 46.60% | -8.17% |
| Income Tax Expenses | 813.49% | 1,639.93% | -22.07% | -96.09% | -1,403.27% |
| Earnings from Continuing Operations | 118.15% | -101.46% | 90.86% | 46.66% | -6.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 118.15% | -101.46% | 90.86% | 46.66% | -6.58% |
| EBIT | 38.08% | 23.96% | 59.77% | 5.20% | 5.86% |
| EBITDA | 39.09% | 24.34% | 61.63% | 5.06% | 6.19% |
| EPS Basic | 118.00% | -99.53% | 91.23% | 51.58% | 3.27% |
| Normalized Basic EPS | 130.43% | -91.54% | 91.33% | 51.45% | 2.08% |
| EPS Diluted | 117.98% | -99.53% | 91.23% | 51.69% | 3.15% |
| Normalized Diluted EPS | 127.69% | -91.54% | 91.33% | 51.45% | 2.08% |
| Average Basic Shares Outstanding | 0.82% | 0.96% | 4.19% | 10.14% | 10.18% |
| Average Diluted Shares Outstanding | 10.77% | 0.96% | 4.19% | 10.14% | 10.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |